Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Effects of Exercise in Patients With Repaired Coarctation of the Aorta (KOREKT)

23 augusti 2026 uppdaterad av: Kevin Pelicon, University Medical Centre Ljubljana

Effects of Exercise on Select Indicators of Cardiovascular Health in Patients With Repaired Coarctation of the Aorta

This interventional study will investigate the effects of high-intensity interval training (HIIT) in adults with repaired coarctation of the aorta. Participants will be randomised into three groups: HIIT performed at home, HIIT performed in a supervised outpatient setting, or a control group receiving usual care. The two HIIT protocols will be identical in intensity and progression, individually prescribed for each patient.

The study will evaluate the effects of HIIT on exercise capacity, health-related quality of life, blood pressure response to exercise, and other select measures of cardiovascular health, including vascular stiffness and endothelial function. In addition, the study will examine the acute effects of a single exercise session on arterial stiffness.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Beräknad)

45

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • Ljubljana, Slovenien, 1000
        • University Medical Centre Ljubljana
      • Maribor, Slovenien, 2000
        • University Medical Centre Maribor

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Beskrivning

Inclusion Criteria:

  • surgically repaired coarctation of the aorta,
  • age at least 18 years, and
  • signed informed consent form.

Exclusion Criteria:

  • residual aortic stenosis (gradient across the narrowing >20 mmHg),
  • presence of ascending aortic aneurysm,
  • recent major cardiovascular event or other event requiring hospitalization (event less than 2 months before inclusion),
  • unstable rhythm disturbances,
  • unstable or low-threshold angina pectoris,
  • NYHA class III or IV heart failure, and
  • pregnancy.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Förebyggande
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Outpatient HIIT

Anticipated number of patients: 15.

Participants will complete a structured high-intensity interval training (HIIT) programme performed in an outpatient setting. Intensity and progression are identical to the home-based HIIT arm.

A structured exercise programme performed under direct supervision in an outpatient/clinical setting on a stationary bicycle or treadmill, consisting of 36 one-hour sessions over 2-4 months (approximately 2-3 sessions per week). Each session will comprise 8 five-minute intervals, each consisting of 2 minutes at 85-95% of the heart rate reached at VO2peak, followed by 3 minutes of active recovery. The interval block will be preceded by a 5-minute active warm-up and followed by a 5-minute active cool-down.

Interval intensity will be individually determined for each patient.

Experimentell: Home-based HIIT

Anticipated number of patients: 15.

Participants will complete a structured high-intensity interval training (HIIT) programme performed independently at home. Intensity and progression are identical to the outpatient HIIT arm.

A structured exercise programme performed independently at home, consisting of 36 one-hour sessions over 2-4 months (approximately 2-3 sessions per week). Each session will comprise 8 five-minute intervals, each consisting of 2 minutes at 85-95% of the heart rate reached at VO2peak, followed by 3 minutes of active recovery. The interval block will be preceded by a 5-minute active warm-up and followed by a 5-minute active cool-down.

Interval intensity will be individually determined for each patient.

Inget ingripande: Control (usual care)

Anticipated number of patients: 15.

Participants will receive usual care, consisting of general counselling on physical activity performed at home, without a structured or supervised exercise training programme.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
VO2peak on cardiopulmonary exercise testing (CPET)
Tidsram: At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
Hypothesis: The outpatient high-intensity interval training (HIIT) programme improves aerobic capacity (measured by VO2peak) more than a home-based HIIT program or usual care.
At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
Health-related quality of life
Tidsram: At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
Hypothesis: The outpatient high-intensity interval training (HIIT) programme improves health-related quality of life, assessed using the standardised SF-36 and EQ-5D questionnaires, more than a home-based HIIT programme or usual care.
At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
Ratio of peak systolic blood pressure to peak workload (mmHg/W) on CPET
Tidsram: At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
Hypothesis: The outpatient high-intensity interval training (HIIT) programme reduces the ratio between peak systolic blood pressure and peak workload achieved during exercise testing more than a home-based HIIT programme or usual care.
At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Mean 24-hour systolic blood pressure
Tidsram: At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
Assessment of average systolic pressure during sleep and wakefulness, measured using 24-hour ambulatory blood pressure monitoring.
At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
Echocardiographic parameters
Tidsram: At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
Assessment of standard echocardiographic measures of cardiac structure and function, including left ventricular global longitudinal strain (GLS).
At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
Endothelial function of the right radial artery (flow-mediated dilation, FMD)
Tidsram: At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
Ultrasound assessment of endothelial function of the right radial artery, measured by flow-mediated dilation (FMD).
At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
Heart rate variability
Tidsram: At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
Assessment of heart rate variability using high-resolution electrocardiography.
At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
Biomarkers associated with vascular stiffness and atherosclerosis
Tidsram: At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
Assessment of circulating biomarkers associated with vascular stiffness and atherosclerosis, including atrial natriuretic peptide (ANP), growth/differentiation factor 15 (GDF-15), matrix metalloproteinase 1 (MMP-1), interleukin-33 receptor (IL-33/ST2), brain-derived neurotrophic factor (BDNF), galectin-3, myeloperoxidase, and tissue inhibitor of metalloproteinase 1 (TIMP-1).
At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
Self-reported physical activity
Tidsram: At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
Self-reported physical activity level, assessed using the standardised International Physical Activity Questionnaire (IPAQ).
At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Body composition
Tidsram: At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
Assessment of body composition using bioelectrical impedance analysis.
At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
Standard laboratory panel
Tidsram: At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
Assessment of standard laboratory parameters: electrolytes, renal function markers, liver function tests.
At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
NT-proBNP
Tidsram: At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
Assessment of NT-proBNP
At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
Extended lipid panel
Tidsram: At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
Assessment extended lipid panel, including Lp(a).
At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
Thyroid hormone level
Tidsram: At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
Assessment of thyroid hormones.
At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 augusti 2026

Primärt slutförande (Beräknad)

1 oktober 2027

Avslutad studie (Beräknad)

1 oktober 2027

Studieregistreringsdatum

Först inskickad

6 augusti 2026

Först inskickad som uppfyllde QC-kriterierna

13 augusti 2026

Första postat (Faktisk)

18 augusti 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

25 augusti 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

23 augusti 2026

Senast verifierad

1 augusti 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

All IPD that underlie results in a publication will be shared upon reasonable request.

IPD-delning som stöder informationstyp

  • STUDY_PROTOCOL
  • ICF

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera